Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors.
about
Epigenetic treatment of solid tumours: a review of clinical trialsClinical Toxicities of Histone Deacetylase Inhibitors.Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial.Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma.Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer.A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma.Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions.The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.Seizure prognosis in brain tumors: new insights and evidence-based managementInhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells.Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.Autophagy induction by histone deacetylase inhibitors inhibits HIV type 1.Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects.MicroRNAs in cancer diagnosis and therapy: from bench to bedside.Toxicological and metabolic considerations for histone deacetylase inhibitors.Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials.Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor.A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification.Essential Role of DNA Methyltransferase 1-mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors.
P2860
Q26773803-9EFDD3E8-8010-4AF7-924B-0B4911E5D79AQ31135325-88050B1D-5F29-431F-ACFF-830BD123302DQ33391851-D216C784-BEFF-4A37-B365-56FEF81F7C74Q33399121-FD962266-C790-4C9E-8C4E-5B6792049FC6Q33400756-C16E0E94-E914-4EBD-9431-0608DC6F9800Q33408000-3541B7D6-193A-438A-AAD9-F0BCE53FC62DQ33427979-D1FCEB86-1466-442C-ADDF-983AC83B694EQ33705588-FC1446B3-F315-4D36-B6D3-58ECA1AE5100Q33829390-7B707C35-F88C-408B-A72F-0734CDB5AC5BQ33829789-ED7F989C-DBF8-4F90-B82C-14C45AB4E072Q33831971-CF1BCA29-E0BE-441A-BE0B-6A7B7D06F3A6Q34488424-EF68555B-6B4D-4B8B-AB69-1C1A00950750Q35008045-DB19BB28-9AE1-4D69-B5CC-AFE8E857AB1AQ35103991-DAEB67F3-F76C-4974-8F15-C8BFA0EF956DQ35939690-639C3E4E-AF92-4139-BCC6-B823655FE3BDQ38057979-B6B5EEF0-8349-4471-B651-89A66B242C5CQ38071321-D03F2485-59C9-43FC-A40C-3674A1D48261Q38081988-5EBC08FE-BBEB-4D46-B76D-B22C7688788AQ38118900-327A42FB-CA21-4A13-B5F7-0BA969721C6FQ47843990-430CA2BF-6B07-413E-8E40-F92B0235CF5CQ51176745-3B2B58E7-9586-46EA-B4DC-0167922B4FE5
P2860
Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Phase I and pharmacokinetic st ...... se patients with solid tumors.
@ast
Phase I and pharmacokinetic st ...... se patients with solid tumors.
@en
type
label
Phase I and pharmacokinetic st ...... se patients with solid tumors.
@ast
Phase I and pharmacokinetic st ...... se patients with solid tumors.
@en
prefLabel
Phase I and pharmacokinetic st ...... se patients with solid tumors.
@ast
Phase I and pharmacokinetic st ...... se patients with solid tumors.
@en
P2093
P1433
P1476
Phase I and pharmacokinetic st ...... ese patients with solid tumors
@en
P2093
James S Hardwick
Kazuhiko Yamada
Noboru Yamamoto
Shinichi Kanazu
Takashi Iwasa
Tetsuya Otsuki
Tomohide Tamura
Yasuhide Yamada
P304
P356
10.1111/J.1349-7006.2009.01237.X
P577
2009-05-31T00:00:00Z